Key Events This Week
30 Mar: Stock opens week at Rs.348.65 amid broad market weakness
1 Apr: Intraday high of Rs.376.20 with a 7.84% surge and strong gap up
2 Apr: Continued gains to Rs.388.75 supported by technical upgrades
3 Apr: MarketsMOJO upgrades rating to Hold reflecting improved fundamentals

Shilpa Medicare Ltd Upgraded to Hold: A Detailed Analysis of Quality, Valuation, Financial Trend and Technicals
2026-04-03 08:10:16Shilpa Medicare Ltd has seen its investment rating upgraded from Sell to Hold as of 2 April 2026, reflecting notable improvements across technical indicators, valuation metrics, and financial performance. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that have driven this change, providing investors with a detailed understanding of the company’s current standing within the Pharmaceuticals & Biotechnology sector.
Read full news article
Shilpa Medicare Ltd Surges 7.84% to Day's High of Rs 376.2 — Outperforms Sector by 5.77 Percentage Points
2026-04-01 10:22:29The Sensex advanced 2.49% on 1 Apr 2026, yet Shilpa Medicare Ltd outpaced the broader market with a 7.84% gain, reaching an intraday high of Rs 376.2. This 5.77-percentage-point outperformance over the Pharmaceuticals & Biotechnology sector’s 2.07% rise signals a distinctly stock-specific surge rather than a mere market tailwind.
Read full news articleShilpa Medicare Ltd Gains 8.11%: Key Technical Shifts and Market Moves This Week
2026-03-28 14:04:39
Key Events This Week
23 Mar: Sharp decline of 3.54% amid broad market sell-off
24 Mar: Intraday high surge of 8.07%, closing at Rs.338.80
25 Mar: Continued gains with 2.01% rise to Rs.345.60
27 Mar: Mixed technical signals as stock closes at Rs.349.95 (+1.26%)

Shilpa Medicare Ltd Shows Mixed Technical Signals Amid Sideways Momentum Shift
2026-03-27 08:02:08Shilpa Medicare Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in its technical momentum, moving from a mildly bearish trend to a sideways stance. Despite a 2.01% gain on 27 Mar 2026, the stock’s technical indicators present a complex picture, with mixed signals across weekly and monthly timeframes, reflecting cautious optimism amid sector headwinds.
Read full news article
Shilpa Medicare Ltd Surges 8.07% to Day's High of Rs 333.7 — Outperforms Sector by 6.47 Percentage Points
2026-03-24 12:01:01The Sensex declined by 1.34% on 24 Mar 2026, while Shilpa Medicare Ltd surged 8.07%, outperforming its Pharmaceuticals & Biotechnology sector by 6.47 percentage points. This sharp single-session gain stands out as a stock-specific event amid a broadly weak market environment.
Read full news article
Shilpa Medicare Ltd is Rated Sell
2026-03-23 10:10:16Shilpa Medicare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news articleFormat of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
09-Apr-2026 | Source : BSEFormat of Initial Disclosure to be made by an entity identified as a Large Corporate.
| Sr. No. | Particulars | Details |
| 1 | Name of Company | Shilpa Medicare Ltd |
| 2 | CIN NO. | L85110KA1987PLC008739 |
| 3 | Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) | 0.00 |
| 4 | Highest Credit Rating during the previous FY | A+ |
| 4a | Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4) | INDIA RATINGS AND RESEARCH PVT. LTD. |
| 5 | Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework | BSE |
Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER
EmailId: CS@VBSHILPA.COM
Designation: CFO
EmailId: apleshdalal@vbshilpa.com
Date: 09/04/2026
Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
06-Apr-2026 | Source : BSESubmission of confirmation certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 31 March 2026.
Closure of Trading Window
25-Mar-2026 | Source : BSEIntimation of Closure of Trading Window under the SEBI (Prohibition of Insider Trading) Regulation 2015 for the fourth quarter and year ended 31 March 2026.
Corporate Actions
No Upcoming Board Meetings
Shilpa Medicare Ltd has declared 100% dividend, ex-date: 17 Sep 25
Shilpa Medicare Ltd has announced 1:2 stock split, ex-date: 06 Nov 15
Shilpa Medicare Ltd has announced 1:1 bonus issue, ex-date: 03 Oct 25
No Rights history available








